No Data
No Data
Express News | Algernon Pharmaceuticals Inc: Announces Non-Brokered Private Placement for Gross Proceeds of $250,000 at Issue Price of $0.12 per Unit
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke...
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch,...
Algernon Pharmaceuticals to Move Forward With Psychedelic Drug DMT Stroke Research Program as Its...
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company
Algernon Pharmaceuticals Inc. (AGN.CN) announced that Seyltx Inc., a privately owned U.S. based drug development company, has closed on its acquisition of Algernon's NP-120 (Ifenprodil) research progr